Cynata Therapeutics gains green light for stem cell clinical trial – Proactive Investors Australia
Proactive Investors Australia |
Cynata Therapeutics gains green light for stem cell clinical trial
Proactive Investors Australia Cynata Therapeutics (ASX:CYP) has received favourable advice from the UK Medicines and Healthcare products Regulatory Agency for its Cymerus™ mesenchymal stem cell product to be used in clinical trials in patients with graft versus host disease. Cynata Receives Favourable Advice from UK Regulatory Authority Cynata to trial Cymerus |
